179 results about "Co medication" patented technology

The invention belongs to the antiviral field of medical chemistry and relates to a novel pyridine derivative shown in a formula (I), a stereisomer, pharmaceutical salt, a solvent compound or a crystalof the pyridine derivative and an application of the pyridine derivative and the stereisomer, pharmaceutical salt, the solvent compound or the crystal in preparing drugs for preventing or treating viral infection diseases such as influenza A and/or influenza B, particularly in preparing a cap dependent endonuclease inhibitor in preventing or treating influenza A and/or influenza B viral infectiondiseases. The compound has remarkable activity for inhibiting influenza endonuclease and influenza DNA, can be independently used or can be combined with a neuraminidase inhibitor, nucleoside medicines, a PB2 inhibitor, a PB1 inhibitor, an M2 inhibitor or other anti-influenza drugs, the influenza infection time is notably shortened, the death rate is remarkably reduced, and the pyridine derivative has very good clinical application prospects.

The invention provides a paclitaxel and diazepinocarbazole compound combined pharmaceutical composition, which comprises active ingredients and pharmaceutically acceptable excipients. The paclitaxel and diazepinocarbazole compound combined pharmaceutical composition is characterized in that the active ingredients are composed of gemcitabine and a diazepinocarbazole compound as shown in the formulaI or pharmaceutically acceptable salts thereof; and mass ratio of gemcitabine to the diazepinocarbazole compound or the pharmaceutically acceptable salts in the active ingredients is (2-8): 1. The pharmaceutical composition has good anticancer curative effect but low toxic or side effect. As the diazepinocarbazole compound is sensitive to gemcitabine, the diazepinocarbazole compound and gemcitabine are combined to produce a synergistic effect. Thereby, clinical dosage of capecitabine is reduced, toxic or side effect caused by large dosage of capecitabine is decreased, and safety index of clinic treatment is raised. The paclitaxel and diazepinocarbazole compound combined pharmaceutical composition has a good clinical application prospect.

The invention discloses a method for treating malignant tumors with joint medicament administration and also discloses an anti-malignant tumor medicinal composition with an antitumor activity and a low toxicity and an anti-malignant tumor medicinal preparation using the medicinal composition as an active component. The method comprises a step of jointing administrating anti-inflammatory medicaments, such as glucocorticosteroids or immunosuppressive agents or biotic agents of target cell factors and a carboxamidotriazole or derivatives or intermediates of the carboxamidotriazole as a medicamentto treat malignant tumors, wherein the anti-inflammatory medicaments have a certain regulation effect on cell factors. Tests prove that the combined medicament can increase the sensitivity of tumor cells to the carboxamidotriazole, so the combined medicament can be used as a broad-spectrum medicament for treating a plurality of malignant tumors, particularly non-small cell lung cancer, colon cancer and the like.

The present invention relates to a pharmaceutical composition for treatment and/or prevention of diseases, use and a use thereof. Specifically, the invention relates to an application of an IDO (indoleamine 2, 3-dioxygenase) inhibitor containing a 1, 2, 5-oxadiazole structure to disease treatment and/or prevention in combination with other drugs. Specifically, the invention relates to a compound which can be used as an IDO inhibitor and contains a 1, 2, 5-oxadiazole structure, or an isomer, metabolite, stable isotope derivative, prodrug, pharmaceutically acceptable salt, hydrate, solvate, eutectic substance or polymorph thereof, and other drugs for combined medication. Compared with single medication, the combined medication has a good synergistic effect on abnormal cell proliferation diseases.

The invention provides a compound used as a DOR receptor antagonist. The structural formula of the compound is as shown in the specification. In comparison with the prior art, the invention expounds a pharmaceutical composition and a preparation containing the compound and an application of the DOR antagonist. The compound can be separately used as a medicine or can be used along with other compounds so as to treat AD (Alzheimer's disease).

The present disclosure describes systems and methods for using patient-specific genomic information to optimize or de-risk therapy for the patient. A user may identify a medication for consideration for prescription to a patient, and a genetic variant of the patient affecting a first protein. An analyzer may identify a second medication targeting the first protein, and may retrieve adverse event data from an adverse event database for patients co-medicated with both the first medication and second medication. The analyzer may determine, based on rates of adverse events, the likelihood of an adverse event occurring through co-medication of the first medication and second medication. Based on the likelihood, and based on a correspondence or non-correspondence between a protein activation characteristic of the first medication and the effect of the genetic variant of the patient, the analyzer may indicate or contra-indicate the first medication for the patient.

The invention discloses a method for detecting adverse reaction signals of combined medication. The method comprises steps of S1 of data acquisition and processing, acquiring ADR original data and performing data processing; S2 of acquisition and standardization of known data of untoward effects of combined medication, and obtaining data as a contrast database of a result evaluation standard through a public searchable database; S3 of integration of new drugs of combined medication, processing two drugs in the data with the same report code in a combined medication report into a new drug in anA+B format; S4 of generation of a new data set, combining individual medication data with the new drug data for combined medication; S5 of signal detection, carrying out data mining and analysis by utilizing an MHRA+ algorithm; S6 of detection signal evaluation, extracting a signal expressed as A+B->ADR in an output result, comparing the signal with a known database, and evaluating effectivenessof the result. The method is advantaged in that combined medication is regarded as new drug combined report data to serve as a combined medication data set, so correlation between medicines of the combined medication and the adverse reaction can be effectively measured, and the method is used for detecting an adverse reaction signal of the combined medication.

The invention provides a combined medicine having efficacy of antineoplastic drugs. The combined medicine consists of chlorogenic acid and a dihydrofolate reductase inhibitor of unit preparations in same or different specifications, and a pharmaceutically acceptable carrier, wherein the chlorogenic acid and the dihydrofolate reductase inhibitor are applied in a simultaneous or separated mode. According to the combined medicine, a synergistic effect can be developed when the chlorogenic acid and the DHFR (dihydrofolate reductase) inhibitor are used in a combined mode, and hematopoietic function injury and weight loss caused by the DHFR inhibitor can be relieved; toxic and side effects of the DHFR inhibitor can be effectively reduced; and the medicine, which combines the chlorogenic acid and the DHFR inhibitor is excellent in curative effect, low in toxicity and good in prospect of clinical application.

The invention provides application of combination of lenvatinib and a PD-1 monoclonal antibody in preparation of an anti-liver cancer drug, and belongs to the technical field of medicines.The combination of low-dose lenvatinib and the PD-1 monoclonal antibody is adopted, infiltration of T lymphocytes in tumor tissue can be enhanced while normalizing of liver cancer blood vessels is promoted, and then the treatment effect on liver cancer is remarkably enhanced; the compound can be applied to liver cancer prevention and treatment. The invention provides a novel treatment combined medication scheme for the treatment of the liver cancer, and has a good application prospect in the aspect of preventing and treating the liver cancer.

The invention relates to an anti-tumour combined pharmaceutical composition and application thereof, and belongs to the field of biological medicines. In order to further improve the cancer treatmenteffect and reduce the drug cost of applying trabectedin at the same time, the invention provides an anti-tumour combined pharmaceutical composition, which comprises an effective amount of enterolactone or a plant lignan precursor capable of being converted into enterolactone in a body, and further comprises an effective amount of trabectedin. According to the invention, experiments prove that combined application of trabectedin and enterolactone can inhibit proliferation, activity, metastasis, invasion and angiogenesis of ovarian cancer and promote tumour cell apoptosis; and, when the two drugs are combined for use, the inhibition effect on the ovarian cancer is stronger than that of a single drug after the dosage of the two drugs is halved. According to the invention, the administration amount of trabectedin is reduced by using the enterolactone with lower cost; the economic burden of a patient is reduced; and the enterolactone can also reduce the side effect of trabectedin. The combined pharmaceutical composition disclosed by the invention can improve the anti-tumour curative effect and promote clinical popularization of trabectedin.

The invention relates to an establishment method and application of a Selpatinib PBPK-RO model. A scientific model established in the invention is used for evaluating the influence of a CYP3A4 inhibitor and a PPIs drug on the PK and PD of a Selpatinib tablet in a human body and predicting and evaluating the change of Selpatinib in the human body.

The invention relates to a combined drug, in particular to a combined drug with anti-tumor activity. The drug comprises elemene substances with anti-tumor effect, nonsteroidal substances with anti-inflammatory effect and one or more medicinal carriers. Such synergic combination ensures the combined drug to have better anti-tumor activity.

The invention belongs to the field of chemical medicines, and in particular relates to new application of polyacetylenes. The invention discloses polyacetylene with a structure shown as a formula (I)and application of pharmaceutically acceptable salts, esters, prodrugs, solvates, polymorphic substances, hydrates or derivatives of the polyacetylene combined with hyperuricemia medicines in preparation of combined medicines for treating hyperuricemia. The invention also provides a hyperuricemia pharmaceutical composition, which comprises the above compound and one of febuxostat or allopurinol. The hyperuricemia pharmaceutical composition can achieve the uric acid reducing effect equivalent to or even better than that of a hyperuricemia medicine in the prior art, but can obviously reduce thetoxic and side effects of the hyperuricemia medicine and improve the safety, and can be used for treating hyperuricemia and gout or gout complications caused by hyperuricemia.

The invention provides a combined medicine for treating colorectal cancer. The combined medicine comprises medicine compositions for simultaneous or respective administration of preparations with thesame or different specifications and units and irinotecan, as well as a pharmaceutically acceptable carrier. The combined medicine can effectively treat colorectal cancer, can reduce side effects, particularly delayed-onset diarrhea, caused by irinotecan, and provides a new choice for clinical medication.

The invention provides a bionic nano preparation based on platelet membrane fragments as well as a preparation method and application of the bionic nano preparation, and belongs to the technical fieldof medicine. By means of drug combination of a cyclin dependent kinase 5(Cdk5) inhibitor and a chemotherapeutic drug, on one hand, tumor cells are killed with chemotherapy, the immune system is activated, content of IFN-gamma is recovered, immunosuppression caused by postoperative stress is relieved, on the other hand, PD-L1 is down-regulated by the Cdk5 inhibitor, IFN-gamma related immune drug resistance is relieved, and through combination of the Cdk5 inhibitor and the chemotherapeutic drug, dual characters of IFN-gamma are changed, the downstream immunosuppressive action of the IFN-gamma is removed, and the positive effect of IFN-gamma is exerted; and meanwhile, the problem of postoperative targeted drug delivery is solved according to the biological trend characteristic of platelets,besides, with improvement of the preparation method, the preparation method of bionic nanoparticles based on the platelet membrane fragments is simple, the drug-loading efficiency is high, and therefore, the bionic nanoparticles have good practical application value.

The invention discloses an oxaliplatin conjugated prodrug, which has a structures represented by a formula 1 and a formula 2, wherein R is -NHR1 or -CH2CH2COR2, wherein R1 is selected from C2-C16 alkyl, and R2 is a group containing a small molecule inhibitor NLG919 containing a dithioethanol active group. The invention further discloses a preparation method and applications of the oxaliplatin conjugated prodrug, wherein the oxaliplatin-micromolecule conjugated drug constructed through chemical bonds is expected to improve the treatment of oxaliplatin and achieve drug combination.

The invention discloses a combined drug for treating tumors, concretely discloses a use of an RAS inhibitor in the preparation of a drug for enhancing the KRAS mutant tumor inhibition effect of an MEKinhibitor, and also discloses a combined drug for treating KRAS mutant tumors. The combined drug for treating KRAS mutant tumors contains different specifications of unit preparations for simultaneously or separately giving an RAS inhibitor and an MEK inhibitor, and a pharmaceutically acceptable carrier. The combined drug can effectively treat the KRAS mutant tumors, has an obviously better effect than the MEK inhibitor and the RAS inhibitor used alone, and has a good clinical application prospect.

The invention discloses a protopanoxadiol derivative and a preparation method thereof, application of the protopanoxadiol derivative as a medicine for treating cancers, and application of the protopanoxadiol derivative in combination with a PD-L1/PD-L2 antibody to improvement of an anti-tumor treatment effect on lung cancers and reduction of side effects. Cancer can be effectively treated through treatment of the combined medicine.

The invention relates to the combined use of at least one monoterpene which can be applied systemically, in particular perorally, and at least one respiratory tract therapeutic agent which can be applied topically, in particular through inhalation, for the prophylactic and/or therapeutic treatment, in particular combination therapy and/or co-medication, of respiratory tract diseases, in particular bronchopulmonary diseases. Through the combined use of the systemic monoterpene with the topical, in particular inhaled respiratory tract therapeutic agent, the effect or efficiency of the topical or inhaled respiratory disease therapeutic agent can be increased significantly, in particular in a synergistic manner, on the one hand, and the required dosage thereof can be reduced significantly on the other hand, combined with the resulting advantages (e.g., avoidance or reduction of side effects).

The invention discloses Survivin dual inhibitor-loaded ferritin nanoparticles as well as a preparation method and application thereof, and application of a Survivin dual inhibitor combined medicine inpreparation of a medicine for treating tumors. The dual inhibitor comprises a small molecule inhibitor YM155 and a protein inhibitor TmSm. The obtained nanoparticles are of a nanocage spherical structure and are free of adhesion, small in particle size, narrow in range, convenient for intravenous injection and good in targeting effect. The nanoparticles can be effectively cut by MMP-2 secreted bycancer cells to release TmSm protein, actively targets the cancer cells through TfR1 on the surfaces of the cancer cells, and releases YM155 in cell nucleuses. The Survivin dual inhibitor-loaded ferritin nanoparticles can realize the synergistic inhibition of Survivin transcription and protein level and obtain a strong anti-tumor effect.

The invention discloses an application of echinatin to preparation of medicines for resisting esophagus cancer, and belongs to the technical field of medicine and pharmacy. For the first time, the inventor of the invention finds that echinatin in vitro level has restraining effects on cell proliferation, transfer and invasion of the esophagus cancer, and the echinatin can effectively restrain thegrowth of the esophagus cancer in vivo. In addition, the inventor of the invention also finds that when the echinatin and 5-fluorouracil are in united medication, the echinatin can increase the sensibility of esophagus cancer cells to the 5-fluorouracil. Besides, blood biochemistry conventional detection of tested animals proves that the echinatin can restrain the growth of the esophagus cancer, and besides, does not have obvious side effects. A new medication selection is provided for treatment of the esophagus cancer.

The invention discloses an application of a polypeptide ABC transporter inhibitor. Polypeptide HX-12C as shown in SEQ ID NO.1 is combined with an ABC transporter substrate chemotherapeutic drug to beapplied to preparation of an ABC transporter mediated multi-drug resistant tumor drug. The ABC transporter mediated multi-drug resistant tumor drug composition is composed of the polypeptide HX-12C shown in SEQ ID NO.1 and the ABC transporter substrate chemotherapeutic drug. The polypeptide disclosed by the invention can inhibit the function of ABC transporter, and can increase the concentration of chemotherapeutic drugs in drug-resistant tumor cells when being combined with ABC transporter substrate chemotherapeutic drugs, thereby inhibiting the proliferation of the drug-resistant tumor cells. The application of the polypeptide ABC transporter inhibitor and ABC transporter substrate chemotherapeutic drug combination in preparation of the ABC transporter mediated multi-drug resistant tumordrug has a wide prospect.